Ogiwara et al. showed that GCLC inhibitors (APR246 and PRIMA-1) could markedly decrease GSH in ARID1A-deficient cancer cells, leading to apoptotic cell death triggered by excessive amounts of ROS [50]. The gene discussed is ARID1A; the disease is cancer.